Cikakken Bayani
COVID-19 Anti-2020-nCoV Sabon Coronavirus
Kayan gwajin coronavirus COVID-19 na'urar gwajin sauri IgM/IgG gwajin TUV
Novel Coronavirus COVID-19 IgG/IgM Diagnostic Rapid
Marufi & Bayarwa
| Cikakken bayanin marufi: daidaitaccen fakitin fitarwa Bayanin isarwa: a cikin kwanakin aiki 7-10 bayan an karɓi biyan kuɗi |
Ƙayyadaddun bayanai
Farashin 68
COVID-19 IgM/IgG Antibody Rapid Test Kit
(Immunochromatography)
SUNA KYAUTA
COVID-19 IgM/IgG Antibody Rapid Test Kit
(Immunochromatography)
AMFANI DA NUFIN
Ana amfani da reagent don gano ƙwayar cuta ta Corona-19 IgM/IgG Antibody a ciki
serum/plasma/jinin gaba daya daidai gwargwado.
KA'IDAR gwaji
Wannan kit ɗin ya dogara ne akan ƙa'idar alamar gwal na gwajin immunochromatographic kuma yana amfani da hanyar kama don gano ƙwayar cuta ta COVID-19 IgM/IgG a cikin samfurin.
KA'IDAR gwaji
COVID-19 IgM
Lokacin da samfurin ya ƙunshi maganin rigakafi na COVID-19 IgM, yana samar da hadaddun tare da antigen alamar gwal (COVID-19 recombinant antigen).Rukunin yana ci gaba a ƙarƙashin aikin chromatography kuma yana haɗuwa tare da antibody mai rufi (Mouse anti-human IgM monoclonal antibody) a layin T don samar da hadaddun da haɓaka launi (T line), wanda shine sakamako mai kyau.Lokacin da samfurin bai ƙunshi maganin rigakafi na COVID-19 IgM ba, ba za a iya samar da wani hadaddun a layin T ba, kuma babu jajayen band da ya bayyana, wanda shine mummunan sakamako.
Ko da kuwa ko COVID-19 IgM antibody yana ƙunshe a cikin samfurin, alamar gwal ɗin ingancin sarrafa antibody (zomo IgG antibody) za ta ɗaure tare da mai rufin antibody (goat anti-zomo IgG antibody) a layin C don samar da hadaddun da haɓaka. launi (Layin C).
COVID-19 IgG
Lokacin da samfurin ya ƙunshi maganin rigakafi na COVID-19 IgG, yana samar da hadaddun tare da antigen alamar gwal (COVID-19 recombinant antigen).Rukunin yana ci gaba a ƙarƙashin aikin chromatography kuma yana haɗuwa tare da antibody mai rufi (Mouse anti-human IgG monoclonal antibody) a layin T don samar da hadaddun da haɓaka launi (T line), wanda shine sakamako mai kyau.Lokacin da samfurin bai ƙunshi maganin rigakafi na COVID-19 IgG ba, ba za a iya ƙirƙirar wani hadaddun a layin T ba, kuma babu jan band da ya bayyana, wanda shine mummunan sakamako.
Ko da kuwa ko COVID-19 IgG antibody yana ƙunshe a cikin samfurin, alamar gwal ɗin ingancin sarrafa antibody (zomo IgM antibody) za ta ɗaure tare da mai rufin antibody (goat anti-zomo IgG antibody) a layin C don samar da hadaddun da haɓaka. launi (Layin C).
BABBAN ABUBUWA
COVID-19 IgM: T-line mai rufi da linzamin kwamfuta anti-human IgM monoclonal antibody, zinariya lakabin kushin m lokaci COVID-19 recombinant antigen, zomo IgG antibody, C-line rufi da goat anti-zomo IgG antibody.
COVID-19 IgG: T-line mai rufi da linzamin kwamfuta anti-human IgG monoclonal antibody, zinariya lakabin pad m lokaci COVID-19 recombinant antigen, zomo IgM antibody, C-line rufi da goat anti-zomo IgM antibody.Samfurin dilution: hada da 20 mM phosphate buffer bayani (PBS)
AJIYA DA KASHEWA
Ajiye kamar yadda aka kunshe a cikin jakar da aka rufe a 4-30 ℃, kauce wa zafi da hasken rana, wuri mai bushe, mai aiki na watanni 12.KAR KA DANKE.Ya kamata a ɗauki wasu matakan kariya a lokacin zafi mai zafi da lokacin sanyi don guje wa yawan zafin jiki ko daskare.Kada a buɗe marufi na ciki har sai an shirya, dole ne a yi amfani da shi cikin sa'a ɗaya idan an buɗe (Humidity≤60%, Temp: 20℃-30℃).Da fatan za a yi amfani da gaggawa lokacin da zafi sama da 60%.
MISALI BUKATAR
1. Ana iya amfani da reagent don maganin jini, plasma da samfuran jini duka.
2. Dole ne a tattara samfurin jini / plasma / duka samfurin jini a cikin akwati mai tsabta kuma bushe.EDTA, sodium citrate, heparin za a iya amfani da su azaman anticoagulants a cikin plasma / duka samfuran jini.Gano nan da nan bayan tattara jini.
3.Serum da samfurori na plasma za a iya adana su a 2-8 ℃ don kwanaki 3 kafin tantancewa.Idan gwajin ya jinkirta fiye da kwanaki 3, samfurin ya kamata a daskare (-20 ℃ ko sanyi).Maimaita daskare kuma narke don fiye da sau 3.Za'a iya adana samfuran jini gaba ɗaya tare da maganin rigakafi a 2-8 ℃ na kwanaki 3, kuma kada a daskare;Ya kamata a yi amfani da samfuran jini gaba ɗaya ba tare da maganin rigakafi ba nan da nan (idan samfurin yana da agglutination, ana iya gano shi ta hanyar magani).
HANYOYIN gwaji
Dole ne a karanta umarnin gaba ɗaya kafin yin gwajin.Bada ikon sarrafa na'urar gwaji don daidaita zuwa zafin jiki na mintuna 30 (20 ℃-30 ℃) kafin gwaji.Kada a buɗe marufi na ciki har sai an shirya, dole ne a yi amfani da shi cikin sa'a ɗaya idan an buɗe (Humidity≤60%, Temp: 20℃-30℃).Da fatan za a yi amfani da gaggawa lokacin da zafi sama da 60%.
Don Serum/Plasma
1. Cire na'urar gwajin daga jakar da aka rufe, sanya shi a kan tsabta mai tsabta da matakin da samfurin ya tashi.
2. Ƙara ɗaya (1) cikakken digo na jini ko plasma (10μl) a tsaye a cikin rijiyar samfurin IgM da IgG daban.
3. Ƙara sau biyu (2) saukad (80-100μl) na samfurin buffer a cikin rijiyar samfurin IgM da IgG daban.
4. Kula da sakamakon gwajin nan da nan a cikin mintuna 15 ~ 20, sakamakon ba shi da inganci sama da mintuna 20.
COVID-19 IgG
Binciken ƙimar daidaituwa na COVID-19 IgG Ab gwajin sauri da kuma nucleic acid reagent a cikin samfuran serum:
Matsakaicin daidaituwa mai kyau = 46 / (46+4) × 100% = 92%,
Matsakaicin daidaituwa mara kyau = 291 / (9+291) × 100% = 97%,
Jimlar adadin daidaituwa = (46+291) / (46+4+9+291) × 100% = 96.3%.
COVID-19 IgM
Binciken ƙimar daidaituwa na COVID-19 IgM Ab gwajin sauri da acid nucleic
reagent a cikin samfurin serum:
Matsakaicin daidaituwa daidai = 41 / (41+9) × 100% = 82%,
Matsakaicin daidaituwa mara kyau = 282 / (18+282) × 100% = 94%,
Jimlar adadin daidaituwa = (41+282) / (41+9+18+282) × 100% = 92.3%
HANKALI
1. Don IN VITRO amfani da bincike kawai.
2. Ya kamata a yi amfani da reagents da wuri-wuri bayan buɗewa.Ba za a iya sake amfani da wannan reagent ba don zubarwa.
3. Na'urar gwajin ya kamata ta kasance a cikin jakar da aka rufe har sai an yi amfani da ita.Idan matsalar rufewa ta faru, kar a gwada.Kada ku yi amfani da bayan ranar karewa.
4.All samfurori da reagents ya kamata a yi la'akari da yiwuwar m da kuma abar kulawa a cikin wannan hanya a matsayin mai cututtuka bayan amfani.
